|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:alsoKnownAs
|
gptkb:ticagrelor
|
|
gptkbp:approvedBy
|
gptkb:acute_coronary_syndrome
gptkb:European_Union
gptkb:United_States
2010
|
|
gptkbp:ATCCode
|
B01AC24
|
|
gptkbp:bindingTarget
|
gptkb:P2Y12_receptor
|
|
gptkbp:bioavailability
|
36%
|
|
gptkbp:brand
|
gptkb:Brilique
gptkb:Brilinta
|
|
gptkbp:CASNumber
|
274693-27-5
|
|
gptkbp:chemicalFormula
|
triazolopyrimidine derivative
|
|
gptkbp:contraindication
|
active pathological bleeding
history of intracranial hemorrhage
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:drugClass
|
gptkb:anticoagulant
|
|
gptkbp:eliminationHalfLife
|
7 hours
|
|
gptkbp:hasMolecularFormula
|
C23H28F2N6O4S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
AZD6140
|
|
gptkbp:indication
|
prevention of thrombotic events
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
P2Y12 receptor antagonist
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
bleeding
bradycardia
dyspnea
|
|
gptkbp:bfsParent
|
gptkb:ticagrelor
|
|
gptkbp:bfsLayer
|
6
|